Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Adis Drug Evaluation"'
Autor:
Kang, Connie, Blair, Hannah A.
Publikováno v:
Drugs
Ofatumumab (Kesimpta®) is a fully human anti-CD20 monoclonal antibody that can be self-administered by patients and is approved in several countries worldwide for the treatment of relapsing forms of multiple sclerosis (MS). In two identical phase II
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16f54e1a39f4c17106e88be008af4542
https://doi.org/10.1007/s40265-021-01650-7
https://doi.org/10.1007/s40265-021-01650-7
Autor:
Zaina T. Al-Salama
Publikováno v:
Targeted Oncology
Durvalumab (IMFINZI®), a fully human monoclonal antibody against programmed cell death-ligand 1 (PD-L1), is approved for use in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of patients with extensive-st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28d6b0384c3f9a8e5151b68e75bd57ff
https://doi.org/10.1007/s11523-021-00843-0
https://doi.org/10.1007/s11523-021-00843-0
Autor:
Anthony Markham
Publikováno v:
Drugs
Avatrombopag (Doptelet®) is an orally administered second generation thrombopoietin receptor agonist (TPO-RA) approved for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory or have an unsatisfactory
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32fddf78b80509a87a6f865a3c182b61
https://doi.org/10.1007/s40265-021-01613-y
https://doi.org/10.1007/s40265-021-01613-y
Autor:
Hannah A. Blair
Publikováno v:
Paediatric Drugs
Subcutaneous secukinumab (Cosentyx®) is a recombinant, fully human, immunoglobulin (Ig) G1κ monoclonal antibody targeted against interleukin (IL)-17A, a proinflammatory cytokine involved in the pathogenesis of psoriasis. Secukinumab is approved in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::271672894aa869d7df9e62bbbe59c9e5
https://doi.org/10.1007/s40272-021-00476-w
https://doi.org/10.1007/s40272-021-00476-w
Autor:
Young-A Heo
Publikováno v:
Drugs
Budesonide/glycopyrronium/formoterol (BREZTRI AEROSPHERE™; TRIXEO AEROSPHERE™) is an inhaled fixed-dose combination of the inhaled corticosteroid (ICS) budesonide, the long-acting muscarinic antagonist (LAMA) glycopyrronium bromide and the long-a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56ce96c72c8e756a9a0c44703c62d2a7
http://europepmc.org/articles/PMC8384783
http://europepmc.org/articles/PMC8384783
Autor:
Yahiya Y. Syed
Publikováno v:
Drugs
Intravenous cefiderocol (Fetroja®; Fetcroja®) is the first siderophore cephalosporin approved for the treatment of adults with serious Gram-negative bacterial infections. Cefiderocol is stable against all four Ambler classes of β-lactamases (inclu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a89a55d8b45f7df8c13f932458b852ab
http://europepmc.org/articles/PMC8383240
http://europepmc.org/articles/PMC8383240
Autor:
Matt Shirley
Publikováno v:
Drugs
Netupitant/palonosetron (NEPA; Akynzeo®), available in oral and intravenous (IV) formulations, is a fixed-dose combination of the neurokinin 1 (NK1) receptor antagonist netupitant (or the prodrug, fosnetupitant, in the IV formulation) and the second
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed6b5ef5721669df6aa152bc714f6c26
https://doi.org/10.1007/s40265-021-01558-2
https://doi.org/10.1007/s40265-021-01558-2
Autor:
Yvette N. Lamb
Publikováno v:
Drugs
Progressive fibrosing interstitial lung diseases (ILDs) involve similar pathophysiological processes, indicating the potential for common approaches to treatment. Nintedanib (Ofev®), an intracellular tyrosine kinase inhibitor (TKI) with antifibrotic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03972f37ede4f68f7c8dca4730cac6f9
https://doi.org/10.1007/s40265-021-01487-0
https://doi.org/10.1007/s40265-021-01487-0
Autor:
Young-A Heo
Publikováno v:
Drugs
Imipenem/cilastatin/relebactam (Recarbrio™) is an intravenously administered combination of the carbapenem imipenem, the renal dehydropeptidase-I inhibitor cilastatin, and the novel β-lactamase inhibitor relebactam. Relebactam is a potent inhibito
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35eeefc4bbd4806e5b70e5e730f91686
http://europepmc.org/articles/PMC7905759
http://europepmc.org/articles/PMC7905759
Autor:
Lesley J. Scott
Publikováno v:
CNS Drugs
Oral siponimod (Mayzent®), a next-generation, selective sphingosine 1-phosphate receptor (S1PR) 1 and 5 modulator, is approved in several countries for the treatment of secondary progressive multiple sclerosis (SPMS), with specific indications varyi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f952a6f8c14bb52311654fd96290b47
https://doi.org/10.1007/s40263-020-00771-z
https://doi.org/10.1007/s40263-020-00771-z